XERS - Xeris Biopharma Holdings, Inc.
Xeris Biopharma NASDAQ: XERS reported a sharp increase in first-quarter 2026 revenue and raised the low end of its full-year revenue outlook, citing strong demand for RECORLEV and continued execution across its commercial portfolio.
Xeris Biopharma Holdings, Inc. (XERS) Q1 2026 Earnings Call Transcript
The headline numbers for Xeris Biopharma (XERS) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
CHICAGO--(BUSINESS WIRE)--XERIS BIOPHARMA REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS.
Xeris Biopharma Holdings, Inc. (NASDAQ: XERS - Get Free Report) has earned an average rating of "Moderate Buy" from the seven research firms that are currently covering the firm, MarketBeat reports. Three investment analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12 month
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its first quarter 2026 financial results before the open of the U.S. financial markets on Thursday, May 7, 2026. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss the Compa.
Xeris Biopharma Holdings, Inc. (NASDAQ: XERS - Get Free Report) insider Beth Hecht sold 16,667 shares of the company's stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $5.99, for a total value of $99,835.33. Following the completion of the sale, the insider owned 1,209,840 shares in the
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that on April 1, 2026, the Compensation Committee of Xeris' Board of Directors granted restricted stock units for an aggregate of 304,975 shares of its common stock to 90 new employee(s) under Xeris' Inducement Equity Plan. Xeris' Inducement Equity.
Xeris Biopharma Holdings, Inc. (XERS) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Xeris Biopharma Holdings, Inc. (XERS) Q4 2025 Earnings Call Transcript
The headline numbers for Xeris Biopharma (XERS) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Xeris Biopharma (XERS) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to a loss of $0.03 per share a year ago.
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the fourth quarter and full year ended December 31, 2025, and provides financial guidance for full year 2026. "Thanks to the entire Xeris organization, 2025 was a transformational year, marked by focused execution, record reven.
Shares of Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) are falling Friday after the company announced a patent infringement lawsuit to protect its drug, Recorlev.
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, announced that its subsidiaries, Xeris Pharmaceuticals, Inc. and Strongbridge Dublin Limited, have filed a patent infringement lawsuit under the Hatch-Waxman Act related to Recorlev® (levoketoconazole) in the United States District Court for the District of New Jer.
Evaluate the expected performance of Xeris Biopharma (XERS) for the quarter ended December 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its fourth quarter and full year 2025 financial results before the open of the U.S. financial markets on Monday, March 2, 2026. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to di.
Recorlev drives robust top-line expansion, while Gvoke and Keveyis provide stable revenue streams in niche, high-need markets, supporting operational leverage. XP-8121, a once-weekly injectable levothyroxine, is 'Phase 3 ready' and targets a large, underserved hypothyroidism market, offering significant long-term upside. XERS trades at a conservative 4.3x forward P/S despite outpacing peers in growth and is showing improving EBITDA.
Xeris Biopharma (NASDAQ: XERS - Get Free Report) and Soleno Therapeutics (NASDAQ: SLNO - Get Free Report) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, analyst recommendations, profitability, earnings and valuation. Analyst Ratings This is a breakdown of current